The Pentagon has recently implemented formal guidelines for mandatory testosterone testing for male service members aged 30 and older. This new policy, announced by Defense Secretary Pete Hegseth in July, focuses on screening for "testosterone deficiency" with the aim of enhancing the operational capabilities of military personnel. However, the program currently excludes female service members, raising questions regarding its necessity and effectiveness among medical experts.
The implementation of testosterone testing aligns with a growing societal interest in the hormone, fueled by health influencers and podcasters who promote testosterone treatments as a means to boost energy, muscle mass, and overall vitality. Despite these claims, many experts argue that the perceived benefits of testosterone therapy are not adequately backed by scientific evidence. Hegseth’s statements appear to mix well-established scientific facts with broader claims that lack substantial support.
The newly released clinical guidance makes it clear that the mandatory testing will initially apply only to male service members. Hegseth's original memo had proposed testing for all troops, but the recent guidance specifies that it pertains solely to "testosterone deficiency in the male service member." The document also notes that guidelines for female service members are currently under review and will be published once approved, yet it remains unclear whether they will have the opportunity to receive evaluations for estrogen-based therapy as they transition through perimenopause.
Testosterone levels naturally decline with age, impacting various aspects of health, including sexual function, mood, and bone density. Experts have debated the best methods for diagnosing and treating low testosterone, with federal studies in the past decade demonstrating that testosterone replacement can improve conditions such as erectile dysfunction and low libido. However, mainstream medical groups typically do not advocate for blanket screening; rather, they recommend testing for men who exhibit symptoms of low testosterone coupled with supporting blood test results.
In contrast to these guidelines, the Pentagon's policy requires testosterone screening for all male personnel aged 30 and older, with the provision that younger members may voluntarily request screenings. While many aspects of the guidance are consistent with medical standards, it also acknowledges the limited advantages of hormone replacement therapy. Specifically, it emphasizes that evidence does not support its use for enhancing energy levels, vitality, physical function, or cognitive abilities. The guidelines highlight the "demonstrated benefits" for sexual function and specific physical measures like bone density.
Importantly, the policy does not mandate testosterone replacement therapy for service members found to have low testosterone levels. It does, however, warn of potential side effects associated with testosterone therapy, such as reduced sperm production, which can pose challenges for any service member wishing to conceive children in the near future.
Deployment conditions present additional complications regarding testosterone therapy. The Pentagon memorandum states that the use of testosterone in deployed environments must address logistical concerns related to supply, storage, and continuity of care prior to deployment. The guidance specifies that injectable testosterone requires controlled room temperature storage and careful management due to its classification as a controlled substance, thus requiring service members undergoing therapy to plan ahead to ensure an adequate supply during deployment.
This cautious approach outlined in the new guidance contrasts with Hegseth's earlier assertions about the necessity of testosterone therapy for maintaining psychological and mental readiness among troops. As the military navigates the complexities of this new policy and its implications for service members, the integration of hormonal health into overall military readiness remains a topic of ongoing debate.
